Advertisement
Screener

Kestra Medical Technologies, Ltd. (KMTS) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Kestra Medical Technologies, Ltd. Financing Cash Flow

Kestra Medical Technologies, Ltd. (KMTS) reported Financing Cash Flow of $22.50 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-09-14

  • Kestra Medical Technologies, Ltd. net cash provided by (used in) financing activities for the quarter ending 2026-07-31 was $22.50M.
  • Kestra Medical Technologies, Ltd. net cash provided by (used in) financing activities for the quarter ending 2026-04-30 was -$185.00K, a 100.09% decline year-over-year.
  • Kestra Medical Technologies, Ltd. net cash provided by (used in) financing activities for the quarter ending 2026-01-31 was $149.18M.
  • Kestra Medical Technologies, Ltd. net cash provided by (used in) financing activities for the quarter ending 2025-10-31 was -$27.00K.
  • Kestra Medical Technologies, Ltd. net cash provided by (used in) financing activities for fiscal 2026 was $147.09M, a 55.46% decline from fiscal 2025.
  • Kestra Medical Technologies, Ltd. net cash provided by (used in) financing activities for fiscal 2025 was $330.26M, a 324.91% increase from fiscal 2024.
  • Kestra Medical Technologies, Ltd. net cash provided by (used in) financing activities for fiscal 2024 was $77.72M.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-07-31$22.50M
10-Q · filed 2026-09-14
$22.31M
derived: sum of 2 quarters · filed 2026-09-14
$171.49M
derived: sum of 3 quarters · filed 2026-09-14
$171.47M
derived: sum of 4 quarters · filed 2026-09-14
2026-04-30-$185.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14
$149.00M
derived: sum of 2 quarters · filed 2026-07-14
$148.97M
derived: sum of 3 quarters · filed 2026-07-14
$147.09M
10-K · filed 2026-07-14
2026-01-31$149.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17
$149.16M
derived: sum of 2 quarters · filed 2026-03-17
$147.28M
10-Q · filed 2026-03-17
$361.98M
derived: sum of 4 quarters · filed 2026-09-14
2025-10-31-$27.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-11
-$1.90M
10-Q · filed 2025-12-11
$212.80M
derived: sum of 3 quarters · filed 2026-09-14
$212.68M
derived: sum of 4 quarters · filed 2026-09-14
2025-07-31-$1.88M
10-Q · filed 2026-09-14
$212.83M
derived: sum of 2 quarters · filed 2026-09-14
$212.71M
derived: sum of 3 quarters · filed 2026-09-14
$212.13M
derived: sum of 4 quarters · filed 2026-09-14
2025-04-30$214.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14
$214.58M
derived: sum of 2 quarters · filed 2026-07-14
$214.01M
derived: sum of 3 quarters · filed 2026-07-14
$330.26M
10-K · filed 2026-07-14
2025-01-31-$119.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17
-$694.00K
derived: sum of 2 quarters · filed 2026-03-17
$115.56M
10-Q · filed 2026-03-17
2024-10-31-$575.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-11
$115.68M
10-Q · filed 2025-12-11
2024-07-31$116.25M
10-Q · filed 2025-09-12
2024-04-30$77.72M
10-K · filed 2025-07-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alphatec Holdings, Inc. (ATEC)United States$1.531B-12.14
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)United States$1.234B-193.02
LEMAITRE VASCULAR INC (LMAT)United States$1.848B33.37
NovoCure Ltd (NVCR)$1.886B-11.87
ARTIVION, INC. (AORT)United States$1.123B-345.09
IRADIMED CORP (IRMD)United States$1.089B52.92
Inspire Medical Systems, Inc. (INSP)United States$1.990B9.55
TANDEM DIABETES CARE INC (TNDM)United States$1.059B-16.57
PROCEPT BioRobotics Corp (PRCT)United States$1.001B-11.77
Beta Bionics, Inc. (BBNX)United States$0.979B-9.66